69449-20-3

Basic information

• Product Name: 4-(bromomethyl)-N,N-dimethylbenzamide
• Synonyms: 4-(bromomethyl)-N,N-dimethylbenzamide
• CAS NO: 69449-20-3
• Molecular Weight: 242.115
• Mol File: 69449-20-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 349.2±25.0 °C(Predicted)
• Density: 1.389±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-(bromomethyl)-N,N-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(bromomethyl)-N,N-dimethylbenzamide(69449-20-3)
• EPA Substance Registry System: 4-(bromomethyl)-N,N-dimethylbenzamide(69449-20-3)

Safety Data

• Hazardous Substances Data: 69449-20-3(Hazardous Substances Data)

Upstream product

• 52780-16-2 4-bromomethylbenzoyl chloride 
• 124-40-3 dimethyl amine 
• 14062-78-3 N,N-dimethyl-4-toluamide 
• 874-60-2 4-methyl-benzoyl chloride 
• 6232-88-8 4-bromomethylbenzoic Acid 

Downstream Products

• 1416064-85-1 C₃₅H₄₆N₄O₄ 

Relevant articles and documents

Pd-catalyzed sp-sp3cross-coupling of benzyl bromides using lithium acetylides

Organolithium-based cross-coupling reactions have emerged as an indispensable method to construct C-C bonds. These transformations have proven particularly useful for the direct and fast coupling of various organolithium reagents (sp, sp2, and sp3) with aromatic (pseudo) halides (sp2). Here we present an efficient method for the cross-coupling of benzyl bromides (sp3) with lithium acetylides (sp). The reaction proceeds within 10 min at room temperature and can be performed in the presence of organolithium-sensitive functional groups such as esters, nitriles, amides and boronic esters. The potential application of the methodology is demonstrated in the preparation of key intermediates used in pharmaceuticals, chemical biology and natural products.

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation

Androgen receptor (AR) signaling functions as a core driving force for the progression of prostate cancer (PCa), and AR has been proved to be an effective therapeutic target even for castration-resistant prostate cancer (CRPC). Herein, structural modification via a fragments splicing strategy was performed based on two lead compounds T3 and 10e, leading to the discovery of a series of 5-methyl-1H-pyrazole derivatives. AR reporter gene assay revealed compounds A13 and A14 as potent AR antagonists. Some of the compounds in this series inhibited growth of PCa LNCaP cells more efficiently than enzalutamide. A13 and A14 also showed improved metabolic stability compared with 10e in human liver microsomes.